Nalaganje...
Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition
BACKGROUND: Poly(ADP-ribose) polymerase inhibitors (PARPi) target tumours defective in homologous recombination (HR). Most BRCA-wild-type (WT) HR-proficient breast cancers are intrinsically resistant to PARP inhibitors, e.g., talazoparib. We evaluated the role of autophagy in this de novo resistance...
Shranjeno v:
| izdano v: | Br J Cancer |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Nature Publishing Group UK
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8007595/ https://ncbi.nlm.nih.gov/pubmed/33473172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-01238-0 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|